Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Neurological Disorders, Mental Health, E...
Phase NA
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to examine the efficacy of this manual for mental health in people with mixed neurological disorders, including post-COVID. These conditions are often associated with cognitive impairment, which may hamper the effects of psychoterapy. Executive functioning and especially the ability to abstract thinking may be useful for individuals using Acceptance and Commitment Therapy. Therefore, the main questions research questions are: * Is this intervention effective in improving mental health? * Do executive functions predict the extent of social participation and mental health at the end of therapy? Participants will take part in 8 weekly group therapy sessions of 100 minutes each.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: ACT-based group therapy — ACT-based group therapy based on the manual "Living Well with Neurological Conditions" published by Hill et al. (2017; NHS Fundation Trust; available: https://goo.gl/aX6qB5). The manual was translated into German and adapted by shortening sessions, simplifying language and adapting exercises based on clinical experience. The publication of the feasibility study for the adapted manual is currently in preparation. The group therapy includes eight weekly sessions with a duration of 100 minutes each. Three to six individuals participate in a group. The therapy is delivered by at least one licensed psychotherapists. A co-therapist might be included based on individual needs of the group members.

Primary Outcomes

  • Depression and Anxiety Stress Scales-21 (Lovibond, 1995) (Before waiting list condition; and pre- and post-intervention (pre and post are presumably 8 weeks apart))
  • Acceptance and Action Questionnaire-Acquired Brain Injury (Sylvester, 2011) (Before waiting list condition; and pre- and post-intervention (pre and post are presumably 8 weeks apart))
  • Wechsler Adult Intelligence Scale - Fourth Edition (Similarities subtest; Wechsler, 2008) (pre- and post-intervention (pre and post are presumably 8 weeks apart))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bielefeld University
Principal Investigators:
  • Katja Werheid, Prof (STUDY_CHAIR) - Bielefeld University
Contact Information
Study Contact:
Simon Ladwig, PhD
+49 (0) 521 106 67533
simon.ladwig@uni-bielefeld.de
Franziska Supe, M.Sc.
+49 (0) 521 106 67533
franziska-marie.supe@uni-bielefeld.de
Simon Ladwig, PhD
+49 (0) 521 106 67533
simon.ladwig@uni-bielefeld.de
Neuropsychologische Hochschulambulanz Bielefeld
Interventions
  • Behavioral: ACT-based group therapy — ACT-based group therapy based on the manual "Living Well with Neurological Conditions" published by Hill et al. (2017; NHS Fundation Trust; available: https://goo.gl/aX6qB5). The manual was translated into German and adapted by shortening sessions, simplifying language and adapting exercises based on clinical experience. The publication of the feasibility study for the adapted manual is currently in preparation. The group therapy includes eight weekly sessions with a duration of 100 minutes each. Three to six individuals participate in a group. The therapy is delivered by at least one licensed psychotherapists. A co-therapist might be included based on individual needs of the group members.
Study Locations (1 sites)
Neuropsychologische Hochschulambulanz Bielefeld, Bielefeld, 33602 Germany
Eligibility Criteria
Inclusion Criteria: * Value above a cut-off of the DASS-21 subscales (depression \> 10, anxiety \> 6, and stress \> 10) * Sufficient cognition and language ability (clinical rating) * Sufficient therapy motivation (clinical rating) Exclusion Criteria: * Behavioral disorders (e.g., high irritability or apathy in clinical rating) * Other severe mental disorder (dementia, psychosis, personality disorders, intellectual disability) * Simultaneous psychotherapy or neuropsychological therapy
Conditions Unipolar Depression, Major Depressive Di...
Phase Not Applicable
Enrollment 98
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach. The device studied, EmoDTx, is a mood-monitoring application that analyzes patients' facial expressions to assess their emotional state. The study aims to compare mood scores obtained via EmoDTx with those of standard depression questionnaires (MADRS, PHQ-9, BDI-II, HAMD-17, QIDS-SR16). It will also provide information on how patients feel about the use of passive monitoring software (without the active involvement of the patient) and how the feedback sent to patients can help in their care. Participants who agree to take part in the study, during a selection visit, will be able to: 1. Install the software on a digital interface (smartphone, computer, etc.) and activate or deactivate it whenever they wish during the 8-week follow-up period. 2. Attend scheduled appointments at the center (a first appointment, then a second 4 weeks later, and a final at 8 weeks) to complete a series of questionnaires, be questioned by the doctor, and fill in other questionnaires on their own. 3. At home, answer questionnaires independently, 2 weeks and 6 weeks after the first appointment. 4. The application's feedback will be deactivated during the first 4 weeks and then reactivated during the final 4 weeks. 5. In parallel, an ancillary study will be conducted on 16 patients enrolled in EMC2FR who accepted and performed the video recording of their structured clinical interview following SCID-5-CV at baseline and 4 weeks.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Change of score EmoDTx (From baseline to 4 weeks)
  • Change of score MADRS administrated by an investigator (From baseline to 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-15
Completion: 2025-12-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 98 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emobot
Collaborators: Nîmes University Hospital
Contact Information
Study Contact:
Tanel PETELOT
+33 6 51 44 26 67
contact@emobot.fr
Clara Roux-Pertus
02 43 53 32 80
clara.roux.pertus@gmail.com
Cabinet médical Sikorav - Chitic - Roux-Pertus
Fabrice Boulet
04 66 68 34 26
fabrice.boulet@chu-nimes.fr
Centre Hospitalier Universitaire de Nîmes
Interventions
N/A
Study Locations (2 sites)
Cabinet médical Sikorav - Chitic - Roux-Pertus, Changé, France 53810 France
Centre Hospitalier Universitaire de Nîmes, Nîmes, France 3090 France
Eligibility Criteria
Inclusion criteria: 1. Outpatients diagnosed with mild to severe unipolar disorder 2. Age ≥ 18 years old 3. Patients willing and able to participate (i.e willing to use the EmoDTx App and having the necessary technical equipment to use it) 4. Patients who read, write and understand French 5. Patients having signed the Patient Informed Consent Exclusion criteria: 1. Patients hospitalized 2. Patients taking more than 75% of the maximal recommended daily dose of benzodiazepines 3. Patients taking more than 75% of the maximal recommended daily dose of antipsychotics 4. Patients taking more than 75% of the maximal recommended daily dose of neuroleptics 5. Patients who did not respond to 10 different pharmacological treatments 6. Patients who attempted suicide within the previous last 6 months and presenting with suicidal ideations 7. Patient presenting with bipolar disorders 8. Patients with a contra-indication to the device under evaluation: * Severe depression requiring hospitalization * Schizophrenic disorders according to DSM 5 classification * Major neurocognitive disorders according to DSM 5 classification * Illiteracy * Subject hospitalized in a healthcare or social institution for reasons other than biomedical research or is deprived of freedom by administrative or judicial decision or is placed under guardianship 9. Patients unable to read, write and understand French 10. Patients with no access to a smartphone or a computer with an internet connection 11. Patients who refuse to sign the Patient Informed Consent 12. Patients already participating in another interventional clinical study
Conditions Esophageal and/or Gastric Varices, Hepat...
Phase NA
Enrollment 110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this prospective cohort study is to evaluate the progression of esophagogastric varices in patients treated with atezolizumab-bevacizumab. Assess the efficacy of primary prophylaxis of small esophageal varices with no risky signs and shortening endoscopic follow-up time intervals to reduce the risk of variceal hemorrhage. Researchers will assess the progression of esophageal varices (EVs) with no bleeding stigmata in patients treated with atezolizumab-bevacizumab therapy at 3, 6, 9, and 12 months with endoscopic examination. Evaluate the effect of shortening the endoscopic follow-up intervals to reduce the risk of variceal bleeding in patients treated with atezolizumab-bevacizumab therapy. Researchers will also assess the efficacy of variceal band ligation in small varices without bleeding stigmata before starting atezolizumab-bevacizumab therapy to reduce the progression of EVs. Participants will undergo history-taking, clinical examination, laboratory investigations, Triphasic CT abdomen with contrast or MRI (for evaluation of tumor site, size and number), abdominal ultrasonography, and upper endoscopy (within 6 months before beginning of systemic therapy and followed up after 3, 6, 9, and 12 months).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Procedure: Esophageal band ligation — upper endoscopy will be performed within 6 months before starting atezolizumab-bevacizumab therapy in HCC patients. Esophageal band ligation for small non-risky varices before starting atezolizumab-bevacizumab therapy. Endoscopy will be repeated 3, 5, 9, 12 months after atezolizumab-bevacizumab therapy

Primary Outcomes

  • esophagogastric varices progression rate (through study completion, an average of 1 year)
  • variceal band ligation in small varices without bleeding stigmata (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-15
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanta University
Principal Investigators:
  • Rania M Elkafoury, MD (PRINCIPAL_INVESTIGATOR) - Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
Contact Information
Study Contact:
Rania M Elkafoury, MD
+201004672358
rania.elkafoury@med.tanta.edu.eg
Nabila A Elgazzar, MD
00201288585733
nabilaelgazzar@med.tanta.edu.eg
Dina H Ziada, MD, head of department
00201117109990
dina.ziada@med.tanta.edu.eg
Tanta University Hospitals
Interventions
  • Procedure: Esophageal band ligation — upper endoscopy will be performed within 6 months before starting atezolizumab-bevacizumab therapy in HCC patients. Esophageal band ligation for small non-risky varices before starting atezolizumab-bevacizumab therapy. Endoscopy will be repeated 3, 5, 9, 12 months after atezolizumab-bevacizumab therapy
Study Locations (1 sites)
Tanta University Hospitals, Tanta, Gharbyea 31516 Egypt
Eligibility Criteria
Inclusion Criteria: * Patients with confirmed advanced HCC (Diagnosed by two imaging modalities or liver biopsy) eligible for atezolizumab-bevacizumab therapy. * Patients with preserved liver function (compensated Child-Pugh A if there is underlying cirrhosis). * Patients with performance status ≤2 at staging work-up. * Patients with no or grade 1 non-risky esophageal varices on pretreatment endoscopic examination. Exclusion Criteria: * Child-Pugh class C patients. * Patients with performance status \>2 at staging work-up. * Vascular disorders and arterial hypertension. * Severe autoimmune disorders. * Patients who lost follow-up. * Pregnant or breastfeeding women. * Unwilling to participate in our study.
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 140
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast cancer (TNBC). Globally, breast cancer is the most common malignancy in women and the second most common cancer overall. The term TNBC is used to define tumours that do not express oestrogen receptors, progesterone receptors and HER2 receptors. TNBC comprises 10 -15% of all breast cancers. It remains the subtype with poorest outcome and there is a significant need to develop new therapies for this group of patients especially. Moreover, the PDL1-negative tumour has demonstrated no benefit from standard 1st line treatment of chemotherapy plus immune checkpoint inhibitors.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Datopotamab Deruxtecan (Dato-DXd) — Patients will receive Dato-DXd 6.0mg/kg, which will be administered by infusion on day 1 of each 21-day cycle.
  • Drug: Durvalumab — Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.

Primary Outcomes

  • PFS is defined as the time from the date of randomisation to the date of first documented confirmed tumour progression (using RECIST 1.1) or death from any cause, whichever occurs first in all patients. (PFS is defined as the time from the date of randomisation to date of first documented confirmed disease progression or death, which ever occurs first, assessed on average up to 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-27
Completion: 2030-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Queen Mary University of London
Collaborators: AstraZeneca
Principal Investigators:
  • Peter Schmid, MD PhD, FRCP (STUDY_DIRECTOR) - Queen Mary University of London
Contact Information
Study Contact:
Peter Schmid, MD PhD, FRCP
+44(0)20 7882 8764
bci-diamond@qmul.ac.uk
Peter Schmid, MD PhD, FRCP
+44(0)20 7882 8764
p.schmid@qmul.ac.uk
Barts Cancer Institute, Centre of Experimental Cancer Medicine
Interventions
  • Drug: Datopotamab Deruxtecan (Dato-DXd) — Patients will receive Dato-DXd 6.0mg/kg, which will be administered by infusion on day 1 of each 21-day cycle.
  • Drug: Durvalumab — Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.
Study Locations (2 sites)
Barts Cancer Institute, Centre of Experimental Cancer Medicine, London, EC1M 6BQ United Kingdom
Barts Health NHS Trust, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Willing and able to provide written informed consent. 2. Ability to comply with the protocol. 3. Female ≥ 18 years of age. 4. Triple-negative disease, defined as tumour cells being: * Negative for ER with \<10% of tumour cells positive for ER on IHC or IHC score (Allred) of ≤3. * Negative for PR with \<10% of tumour cells positive for PR on IHC or IHC score (Allred) of ≤3 or PR unknown, and * Negative for HER2 with 0, 1+ or 2+ intensity on IHC and no evidence of amplification on ISH. 5. PDL1 negative, defined as 22C3 CPS\<10. 6. Patients must have: * at least one lesion, not previously irradiated, that can be measured accurately at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥ 15mm) with computed tomography (CT) or magnetic resonance imaging (MRI) performed within 28 days prior to randomisation which is suitable for accurate repeated measurements, or * lytic or mixed (lytic + sclerotic) bone lesions in the absence of measurable disease as defined above; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible. Patient that cannot be assessed by the CT or MRI should be excluded from the study. 7. Representative formalin-fixed paraffin embedded (FFPE) breast tumour samples with an associated pathology report from the primary or recurrent cancer that are determined to be available and sufficient for central testing OR tumour accessible for biopsy. 8. ECOG performance status 0-1. 9. Life expectancy ≥12 weeks. 10. Adequate haematologic and end-organ function within 28 days prior to the first study treatment defined by the following: * Absolute neutrophil count ≥ 1500 cells/μL (1.5 x 109/L) (without granulocyte) colony-stimulating factor support within 2 weeks prior to Cycle 1, Day 1). * WBC \> 2500/μL (2.5 x 109/L). * Platelet count ≥ 100,000/μL (100 x 109/L) (transfusion not permitted within 28 days of study medication). * Haemoglobin ≥ 9.0 g/dL (90g/L) with no blood transfusions (packed red blood cells). * Serum albumin ≥ 3g/dL. * AST (SGOT) or ALT (SGPT) and ALP ≤ 2.5 times the institutional upper limit of normal (ULN), bilirubin ≤ 1.5 x ULN (patients with liver metastases who have AST or ALT ≤ 5 x the institutional ULN may be enrolled). * aPTT ≤ 1.5 × the institutional ULN, INR \<1.5 and absence of evidence of impaired hepatic synthesis function. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. * Serum Creatinine ≤ 1.5 x institutional ULN. * Glomerular filtration rate ≥ 40mL/min as assessed by standard methodology at the investigating center (i.e., Cockcroft Gault, MDRD or CKD-EPI formulae, EDTA clearance or 24 h urine collection). * No evidence of haematuria: +++ on microscopy or dipstick. 11. Patients of childbearing potential are eligible provided they have a negative serum or urine pregnancy test on Cycle 1, Day 1 (within 72 hours) of study treatment, preferably as close to the first dose as possible. Patients must agree to use adequate contraception, defined as those methods with a failure rate of \< 1 % per year beginning 14 days before the first dose of study drug and for 7 months after the last dose of study drug. Also, participants must not donate, or retrieve for their own use, ova at any time during this study and for at least 7 months after the last dose of treatment. Preservation of ova should be considered prior to randomisation or the first dose of study intervention. 12. Body Weight \> 30 kg. Exclusion Criteria: 1. Prior chemotherapy, immunotherapy (including durvalumab) or treatment with PARP inhibitors for advanced or metastatic breast cancer. 2. Prior treatment with immune checkpoint inhibitors (eg atezolizumab, pembrolizumab) or DNA topoisomerase I or TROP2- or HER2-targeting ADCs and TROP2 targeted therapy in the (neo)adjuvant setting within 6 months from the end of treatment and randomisation into this study. 3. Patients with prior allogeneic stem cell or solid organ transplantation. 4. Patients must not have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent), or had oral or IV steroids for 14 days prior to the first dose of study drug; the use of intranasal, inhaled corticosteroids topical steroids, or local steroid injections, physiologic replacement doses of glucocorticoids (i.e. for adrenal insufficiency) and mineralocorticoids (e.g. fludrocortisone) or steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication is allowed. 5. Administration of a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. 6. Active or prior documented autoimmune or inflammatory disorders including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, , rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis , Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The following are exceptions to this criterion: * Patients with vitiligo or alopecia * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement therapy * Any chronic skin condition that does not require systemic therapy * Patients without active disease in the last 5 years may be included * Patients with celiac disease controlled by diet alone 7. History of idiopathic pulmonary fibrosis (including pneumonitis or interstitial lung disease), drug-induced pneumonitis, radiation pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia) requiring steroids, or evidence of active pneumonitis on screening chest CT scan. 8. Active infection requiring systemic therapy. 9. History of HIV infection. 10. Known active hepatitis infection (defined as having a positive hepatitis B surface antigen \[HBsAg\] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen \[anti-HBc\] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. 11. Known history of active tuberculosis (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice). 12. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent. 13. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the study protocol. 14. Concurrent treatment with other experimental drugs or participation in another clinical trial with therapeutic intent within 28 days prior to randomisation. 15. Pregnant and lactating female patients. 16. Major surgical procedure within 4 weeks prior to randomisation or anticipation of need for a major surgical procedure during the c
Conditions Breast Cancer Screening
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to construct an auxiliary diagnostic model for breast cancer by methylation markers. The study will collect blood and tissue samples from participants with breast cancer and benign disease for whole-genome methylation sequencing. It will screen methylation markers and develop a methylation auxiliary diagnosis model to distinguish between breast cancer and non-cancer.

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Primary Outcomes

  • Establish DNA methylation profiles of two populations by collecting tissues and peripheral blood related to benign and malignant breast nodules. (12 months)
  • Based on DNA methylation profiles, systematically evaluate the signal, noise, and complementarity of methylation biomarkers and ultimately form a set of diagnostic biomarker combinations for breast malignant nodules. (12 months)
  • Further develop a methylation assisted diagnostic model that can effectively distinguish between benign and malignant breast nodules. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-15
Completion: 2026-08-31
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Geneplus-Beijing Co. Ltd.
Collaborators: Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Ruiqi Zhong
+86-10-13501076800
13501076800@163.com
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Interventions
N/A
Study Locations (1 sites)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria for All the Participants: * With confirmed pathological diagnosis and molecular subtyping results * Ability to provide a written informed consent Exclusion Criteria for Cancer Arm Participants: * Patients with a history of or currently suffering from other malignancies * Pregnant or planning to become pregnant female patients * Patients who have received cancer treatment, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, before blood draw * Patients with a history of blood transfusion within the past month * Patients with a known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation * Patients with persistent fever or undergoing anti-inflammatory treatment within 14 days before blood draw * Any other conditions that the researcher deems may make the patient unsuitable for inclusion in the study or may interfere with the completion of the study * Patients in poor physical condition who are not suitable for blood draw * Patients who cannot provide informed consent or refuse blood draw Exclusion Criteria for Benign Diseases Arm Participants: * History of malignancies * Current malignancies or precancerous lesions
Conditions Cannabis Use, Depression
Phase NA
Enrollment 280
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to investigate the effects of cannabis on brain function among adolescents with depression.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Neuroimaging Investigation — Participants will undergo fMRI neuroimaging at two timepoints, at the start of the study and at the 1 year follow up. The fMRI is one hour in duration. During the fMRI, participants will complete two tasks investigating diverse aspects of reward circuitry activity. After this is completed, participants will be followed up for another year clinically.

Primary Outcomes

  • Depression Severity measured by the Beck Depression Inventory (BDI) (Up to 3 years)
  • Anhedonia Severity measured by the Temporal Experience of Pleasure Scale (TEPS) (Up to 3 years)
  • Cannabis Use measured by the Daily Frequency, Age of Onset, and Quantity of Cannabis Use (DFAQCU) Inventory (Up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-04
Completion: 2029-06-01
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: true
Enrollment: 280 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: Nathan Kline Institute for Psychiatric Research, National Institute on Drug Abuse (NIDA)
Principal Investigators:
  • Vilma Gabbay, MD, JD, MS (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Vilma Gabbay, MD, JD, MS
305-243-5510
vxg595@miami.edu
Lilly Mcleod, BS
305-243-1549
lxm1750@miami.edu
University of Miami Clinical Research Building
Lisle Allen, BS
3052435510
lxa2171@miami.edu
University of Miami Clinical Research Building
Interventions
  • Behavioral: Neuroimaging Investigation — Participants will undergo fMRI neuroimaging at two timepoints, at the start of the study and at the 1 year follow up. The fMRI is one hour in duration. During the fMRI, participants will complete two tasks investigating diverse aspects of reward circuitry activity. After this is completed, participants will be followed up for another year clinically.
Study Locations (2 sites)
University of Miami Clinical Research Building, Miami, Florida 33136 United States
Nathan Kline Institute, Orangeburg, New York 10962 United States
Eligibility Criteria
Inclusion criteria at baseline. * Cannabis users: To capture a wide range of cannabis use frequency, meeting DSM-5 criteria for cannabis use disorder will not be required. However, in order to ensure sufficient exposure, we will require majority of adolescents with cannabis use to have a significant cannabis use (self-reported use on more or equal to 10 of the prior 30 days and positive THC urine toxicology). * Depression: Similarly, to capture a wide range of depression illness severity, we will allow participants with subthreshold depression, defined as a raw severity score of \>=30 on the Children's Depression Rating Scale-Revised (CDRS-R, for ages 14-17) and as a raw severity score of \>=12 on the Montgomery Asberg Depression Rating Scale (MADRS, for ages 18-20). However, we plan for at least 50% of participants with depressive symptoms to have a raw severity score of \>=40 on the CDRS-R and of \>=20 MADRS, which are considered reliable for depression. Additionally, we will allow participants with a research diagnosis of Major Depressive Disorder as defined by the MINI, even with a CDRS-R score below 30 or a MADRS score below 12. Moreover, because there could be individuals without MDD who have current depressive symptoms, individuals who lack a diagnosis of a depressive disorder but have a CDRS-R score of 30 (or higher) or a MADRS score of 12 (or higher) will be allowed. Through careful recruitment, we will ensure distributions of depression severity. Based on our prior studies employing similar criteria, we anticipate that anhedonia, anxiety and depression severity scores will be normally distributed in our samples. Exclusion criteria. All participants: * Psychotropic medication free for more than 1 month (or more than three months for medications with a long half-life such as fluoxetine) prior to study enrollment. We have successfully enrolled hundreds of psychotropic medication-free depressed adolescents and young adults to date. Psychotherapy will be allowed. * MRI contraindications such as claustrophobia, metallic ink tattoos, orthodontic braces, or pacemakers * Positive pregnancy tests * Neurological illnesses and medical conditions such as unique pain syndromes (e.g. multiple sclerosis, rheumatoid arthritis) * Estimated full-scale IQ \<=80 to ensure that participants have the ability to understand the study * Current SUD other than cannabis or nicotine. Excluding nicotine use will limit generalization of our findings and impact feasibility. Similarly, alcohol use will be allowed as long as it is not hazardous and does not meet criteria of a DSM-5 disorder (AUDIT-C \>5). Therefore, nicotine and alcohol use will be allowed and controlled for. Alcohol and cannabis use (assessed based on breathalyzer from alcohol and self-report for cannabis/THC) on the day of the scan will result in rescheduling the scan as it can affect MRI data. * Certified for or self-reported medical cannabis use, or intent to become certified, current stimulant use (methamphetamine or cocaine) by self-report or urine toxicology. Adderall and Vyvanse for ADHD will be allowed as long as use is temporarily paused medication usage at least 3 days before neuroimaging visit. If medication is not discontinued on scan day, scanning at that time will be up to PI discretion. * Oral contraceptives will be allowed and controlled for in order to maximize recruitment of older adolescents. Depressed THC non-users: * DSM-5 diagnoses of bipolar disorder, psychotic disorders, autism spectrum disorders, and all non-cannabis substance-related disorders will be exclusionary. However, anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD) are not uncommon among depressed individuals and will be allowed as long as depressive symptoms are primary. Our focus on behavioral constructs aims to address comorbidity and mechanistic overlap among psychiatric disorders. Were these diagnoses exclusionary, the sample would be highly atypical of depression. * Self-injurious acts (e.g. cutting) and suicidal ideations (SI) without a specific plan (defined as passive SI) are common in adolescent depression and will be allowed. However, if SI constitutes an imminent risk to self or others (defined as active SI), the adolescent will be withdrawn from the study and emergency procedures will be initiated immediately, including ER admission (see Protection of Human Subjects). Healthy controls will have no lifetime history of any major psychiatric diagnoses and no use of any THC.
Conditions Breast Cancer, Early-stage Breast Cancer...
Phase PHASE2
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in situ treated with 5-fraction whole breast irradiation (WBI) with a simultaneous integrated tumor bed boost (SIB). SIB refers to the technique tumor bed boost given at the same time as standard radiation therapy. The FAST-Forward trial previously showed that a 1-week course of radiotherapy had similar effects to the traditional 3-week course for early-stage breast cancer after surgery. Given these favorable results, a 5-fraction WBI regimen is appealing for many patients who wish to minimize the number of treatment visits while still reducing their risk of recurrence. Generally, tumor bed boosts further decrease the risk of recurrence, but in the setting of 5-fraction WBI, a more traditional sequential boost technique is utilized.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Breast Radiotherapy — The tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with whole breast irradiation (WBI).

Primary Outcomes

  • Rate of any moderate-marked adverse effects (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-19
Completion: 2028-02
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Principal Investigators:
  • Ethan Steele, MD, MS (PRINCIPAL_INVESTIGATOR) - UNC Lineberger Comprehensive Cancer Center
Contact Information
Study Contact:
Chasity McCue
919-966-4432
chasity_mccue@med.unc.edu
Cory Grreenwood
919-445-4929
cory_greenwood@med.unc.edu
Claire Kowalczyk
919-966-4432
claire_kowalczyk@med.unc.edu
University of North Carolina
Interventions
  • Radiation: Breast Radiotherapy — The tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with whole breast irradiation (WBI).
Study Locations (1 sites)
University of North Carolina, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Inclusion Criteria: * Willing and able to provide written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. * Women ≥ 50 years of age with confirmed de novo invasive carcinoma of breast or ductal carcinoma in situ. * Subjects with completed breast-conserving surgery (BCS) with or without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). * Subjects planned to receive either SOC whole breast 3D conformal radiation therapy (3D CRT) or SOC whole breast intensity modulated radiation therapy (IMRT) with standard dose tumor bed boost. * Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial, per the discretion of the treating radiation oncologist. * Enrollment in another clinical trial is allowed if there is no interference with interventions on this trial per discretion of the Principal Investigator. Exclusion Criteria: * Receipt of concurrent breast reduction involving tissue rearrangement in the lumpectomy cavity (so that boost cannot be accurately targeted). * Synchronous bilateral breast cancer requiring bilateral radiation therapy. * Clinical or imaging evidence of distant metastases. * Prior ipsilateral breast or thoracic radiation. * Autoimmune conditions * Collagen Vascular Disease (such as systemic lupus erythematosus, scleroderma, dermatomyositis, among others) * Patients with pT4 tumors. * Patients recommended to receive regional nodal irradiation with associated radiation risks
Conditions Breast Neoplasms, Quality of Life
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective pilot study examining the couple's dyadic attitudes from diagnosis to 24 months later when one member is affected by illness and the adaptive strategies the couple employs when stressful events occur.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Nursing care model — Describe relation between resilience, quality of life and depression and marital adaptation in the population considered from diagnosis to 24 months later.

Primary Outcomes

  • EORTC-QLQ C30 (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-14
Completion: 2025-11-14
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Regina Elena Cancer Institute
Contact Information
Study Contact:
Ilaria Farina, MSN
0652666804
ilaria.farina@ifo.it
Silvia Takanen, Dr
silvia.takanen@ifo.it
Ilaria Farina, Dr
0652666804
ilaria.farina@ifo.it
IRCCS Regina Elena National Cancer Institute
Interventions
  • Behavioral: Nursing care model — Describe relation between resilience, quality of life and depression and marital adaptation in the population considered from diagnosis to 24 months later.
Study Locations (1 sites)
IRCCS Regina Elena National Cancer Institute, Roma, Rome 00144 Italy
Eligibility Criteria
INCLUSION CRITERIA: * Woman diagnosed with stage 1, 2 or 3 breast cancer * age\> 18 years (patient and partner) * The partner must have lived with the woman for at least 6 months at diagnosis and treatment * Patients under treatment at the radiotherapy clinic * Subjects available and able to answer questionnaires, interviews, and / or participate in focus groups * Informed consent EXCLUSION CRITERIA: Cognitive deficits and / or inability to comply with the provisions of the study
Conditions Breast Cancer Metastatic, Breast Carcino...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Invasive ductal carcinoma is the most common type of invasive breast cancer. In cases where axillary lymph node metastases are diagnosed through screening, they can be found in up to 25% of cases, and in symptomatic cases, up to 60% of cases. The clinical detection accuracy of axillary lymph node metastases is only 33%. Accurate staging of lymph nodes in breast cancer patients is crucial for both prognosis and treatment. Ultrasonography is much more sensitive than physical examination alone for determining axillary lymph node involvement in breast cancer staging. Fine needle aspiration biopsy or core biopsy is diagnostic in lymph nodes that cannot be clarified solely by ultrasonography or are suspicious. Although biopsy sampling yields high diagnostic rates, it requires an experienced pathologist and sometimes takes weeks to yield results. Therefore, there is a need for faster and less costly diagnostic methods for diagnosing axillary metastases. Among thyroid cancers, papillary thyroid carcinomas, a malignancy in which the lymph node washout method is used to determine lymph node metastasis, are the most common. In papillary thyroid cancer patients, washout sampling of neck lymph nodes by fine needle aspiration, searching for thyroglobulin, a protein normally found in thyroid tissue, is considered one of the most valid methods for detecting lymph node metastasis in this cancer. In recent years, immune checkpoint molecules associated with cancer have been widely used as biomarkers and agents in both diagnosis and treatment for cancer patients. There are numerous publications in the literature regarding the expression of immune checkpoint molecules such as Programmed cell death protein 1 (PD-1), Programmed death ligand 1 (PD-L1), and The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) on the cell surface of breast cancer patients. Although the natural soluble forms of receptors and ligands of immune checkpoint molecules exist and they are important components of immune regulation, their exact mechanisms of action have not yet been determined. There are five studies in the literature evaluating the status of soluble immune checkpoint molecules in breast cancer patients, with one being a review article. It is highly likely that immune checkpoint molecules found on both the cell surface and soluble in blood and body fluids are also present in tumor metastatic regions. There is no study using these immunological biomarkers to determine metastasis in invasive ductal carcinoma patients with metastatic axillary lymph nodes ın the literature. In this study, the investigators will evaluate the soluble levels of immune checkpoint molecules in washout fluids obtained from metastatic axillary lymph nodes and benign lymph nodes in patients with invasive ductal breast carcinoma, and will assess the effectiveness of these immune checkpoint molecules and the washout method in diagnosing metastasis.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Crossover Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Malign Lymph Node Washout — During routine axillary lymph node sampling, which is performed as part of standard staging using imaging methods, a washout sample (which is not not routinely applied ) will be obtained by injecting 1 cc of 0.9% saline into axillary lymph nodes suspected to be metastatic. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 1.
  • Diagnostic Test: Benign Lymph Node Washout — Description: During the biopsy performed to histopathologically confirm the benign nature of a radiologically presumed benign axillary lymph node, a washout sampling will also be conducted by injecting 1 cc of 0.9% saline into benign lymph node. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 2.

Primary Outcomes

  • The immune checkpoints in lymph node washout fluid (3 monthts)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-01
Completion: 2025-10-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul Training and Research Hospital
Contact Information
Study Contact:
Ufuk Oguz Idiz, Assoc. Prof. MD. PhD
+905062044714
ufukidiz@gmail.com
Mert Ali Dolek, MD
+905364310364
mertdolek@gmail.com
Ufuk Oguz Idiz, Assoc.Prof. MD. PhD
+905062044714
ufukidiz@gmail.com
Istanbul Training and Research Hospital
Interventions
  • Diagnostic Test: Malign Lymph Node Washout — During routine axillary lymph node sampling, which is performed as part of standard staging using imaging methods, a washout sample (which is not not routinely applied ) will be obtained by injecting 1 cc of 0.9% saline into axillary lymph nodes suspected to be metastatic. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 1.
  • Diagnostic Test: Benign Lymph Node Washout — Description: During the biopsy performed to histopathologically confirm the benign nature of a radiologically presumed benign axillary lymph node, a washout sampling will also be conducted by injecting 1 cc of 0.9% saline into benign lymph node. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 2.
Study Locations (1 sites)
Istanbul Training and Research Hospital, Istanbul, 34098 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Histopathologically proven invasive ductal carcinoma * Patients who will have neoadjuvant therapy Exclusion Criteria: * The fine-needle aspiration biopsy (FNAB) result of the suspected metastatic lymph node is negative. * The FNAB result of the presumed healthy lymph node is malignant. * They refuse to participate in the study. * They have another primary malignancy. * They are pregnant. * They have a history of immunodeficiency.
Conditions ER+/HER2- Breast Cancer
Phase PHASE2
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of high-intensity focused ultrasound (HIFU) combined with toripalimab and chemotherapy as neoadjuvant therapy for ER+/HER2- breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: HIFU — HIFU therapy is administered to the targeted breast lesion site.
  • Drug: Toripalimab — 240 mg, IV infusion, Q3W
  • Drug: nab-Paclitaxel (nab-P) — 125 mg/m2, IV infusion, QW
  • Drug: Epirubicin (E) — 90 mg/m2, IV infusion, Q3W
  • Drug: Cyclophosphamide (C) — 600 mg/m2, IV infusion, Q3W

Primary Outcomes

  • Total Pathological Complete Response (tpCR) Rate: ypT0/Tis, ypN0 (Up to approximately 30 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-04
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Principal Investigators:
  • Yiding Chen (PRINCIPAL_INVESTIGATOR) - 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Contact Information
Study Contact:
Yiding Chen
+86 0571 87783759
ydchen@zju.edu.cn
Shijie Wu
shijiewu@zju.edu.cn
Yiding Chen
+86 0571 87783759
ydchen@zju.edu.cn
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Interventions
  • Procedure: HIFU — HIFU therapy is administered to the targeted breast lesion site.
  • Drug: Toripalimab — 240 mg, IV infusion, Q3W
  • Drug: nab-Paclitaxel (nab-P) — 125 mg/m2, IV infusion, QW
  • Drug: Epirubicin (E) — 90 mg/m2, IV infusion, Q3W
  • Drug: Cyclophosphamide (C) — 600 mg/m2, IV infusion, Q3W
Study Locations (1 sites)
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-75 years. 2. Invasive breast cancer without distant metastasis, including either T1c-T4 (≥ 2 cm), cN0-cN3. 3. Histopathologically confirmed ER-positive/HER2-negative, PR \< 20% or Ki67 ≥ 20%, Grade 3 breast cancer. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Exclusion Criteria: 1. Female patients during pregnancy or lactation. 2. Diagnosis of bilateral breast cancer, occult breast cancer, or distant metastasis confirmed by pathology. 3. Has an active autoimmune disease that has received systemic treatment in the last 2 years. 4. Has a known history of human immunodeficiency virus (HIV), hepatitis B, or known active hepatitis C virus infection. 5. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. 6. Has a known history of invasive malignancy that required systemic treatment in the last 5 years. 7. Uncontrolled concomitant diseases include severe infection, liver disease, cardiovascular disease, kidney disease, respiratory disease, diabetes, and others requiring systemic treatment.
Conditions Hypertensive Disorder of Pregnancy
Phase NA
Enrollment 1200
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this interventional study is to learn from patients and healthcare providers at 4 health institutions (study sites) in Abuja and Kano in Nigeria what ways to best develop the content of a Hypertensive Disorders of Pregnancy ( HDP) Management package for pregnant women, and evaluate the effectiveness of implementing this package in improving cardiovascular health of pregnant women. The main question it aims to answer is: Will a contextualized home BP monitoring program lead to better BP control among patients with HDP in Nigeria?

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Hypertension Disorders of Pregnancy (HDP) Implementation Bundle — The HDP Implementation Bundle will consist of 4 main blocks namely; patient education, home BP monitoring, a contextualized follow-up protocol and provision of free anti-hypertensives if need. Collectively, these will lead to design and development of a contextualized home BP monitoring program.

Primary Outcomes

  • Between group difference in change in systolic BP from baseline to 6-week follow-up (Baseline to 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-08
Completion: 2029-06
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Zainab Mahmoud, MD, MSc (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Dike Ojji, MBBS, PhD
+234-806-009-4456
dike.ojji@uniabuja.edu.ng
Kamilu Karaye, MBBS, PhD
+2348037042171
kkaraye@yahoo.co.uk
Elizabeth Tomilola-Emmanuel, MBBS
+2348133910560
tomilolaemmanuel@yahoo.com
National Hospital, Abuja
Interventions
  • Other: Hypertension Disorders of Pregnancy (HDP) Implementation Bundle — The HDP Implementation Bundle will consist of 4 main blocks namely; patient education, home BP monitoring, a contextualized follow-up protocol and provision of free anti-hypertensives if need. Collectively, these will lead to design and development of a contextualized home BP monitoring program.
Study Locations (4 sites)
National Hospital, Abuja, Abuja, Nigeria
University of Abuja Teaching Hospital, Abuja, Nigeria
Aminu Kano Teaching Hospital, Kano, Nigeria
Murtala Muhammad Specialist Hospital, Kano, Nigeria
Eligibility Criteria
Inclusion Criteria: * Postpartum adults (\>18 years) * postpartum emancipated minors (in accordance with the Nigerian guidelines for young persons' participation in research and reproductive health services) * with diagnosis of HDP prior to delivery delivered at one of the participating sites able to provide informed consent. Exclusion Criteria: * unable to provide consent.
Conditions Breast Cancer Stage IV, Triple -Negative...
Phase PHASE3
Enrollment 246
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to response (TTR), two-year OS rate, biomarker analysis, and quality of life (QoL).Safety: Assess and compare adverse event incidence and severity.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Camrelizumab+Apatinib+Eribulin — Camrelizumab (200 mg, IV, Day 1) + Apatinib (250 mg, PO, QD) + Eribulin (1.4 mg/m², IV, Day 1 and Day 8) administered in 21-day cycles.
  • Drug: Physician's choice chemotherapy — Physician's Choice Chemotherapy

Primary Outcomes

  • Progression-Free Survival (Time from enrollment to the occurrence of predefined events, including disease progression or death, whichever came first, assessed up to 60 months.)
  • Overall Survival (From date of randomization until the date of death from any cause, assessed up to 120 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-02-21
Completion: 2029-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 246 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Jieqiong Liu, M.D., Ph.D.
+86-020-34071156
liujieqiong01@163.com
Jieqiong Liu, M.D., Ph.D.
+86-020-34071156
liujieqiong01@163.com
Sun Yat-sen Memorial Hospital
Jieqiong Liu, M.D., Ph.D
Sun Yat-sen Memorial Hospital
Interventions
  • Drug: Camrelizumab+Apatinib+Eribulin — Camrelizumab (200 mg, IV, Day 1) + Apatinib (250 mg, PO, QD) + Eribulin (1.4 mg/m², IV, Day 1 and Day 8) administered in 21-day cycles.
  • Drug: Physician's choice chemotherapy — Physician's Choice Chemotherapy
Study Locations (7 sites)
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong China
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou China
Wuhan Union Hospital of China, Wuhan, Hubei China
Yichang Central People's Hospital, Yichang, Hubei China
Xiangya Hospital of Central South University, Changsha, Hunan China
The Central Hospital Of Yong Zhou, Yongzhou, Hunan China
Changhai Hospital of Shanghai, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. The subject voluntarily agrees to participate in this study and signs an informed consent form (ICF). 2. Female subjects aged ≥18 and ≤70 years on the date of signing the ICF. 3. Pathologically confirmed advanced triple-negative breast cancer (TNBC), defined as ER-negative (IHC ER-positive percentage \<1%), PR-negative (IHC PR-positive percentage \<1%), and HER2-negative (IHC-/+, or IHC++ but FISH/CISH-), with at least one measurable lesion per RECIST v1.1 criteria. 4. Patients who have received at least 1 and up to 4 lines of prior systemic therapy for metastatic or locally advanced unresectable triple-negative breast cancer (TNBC) with disease progression. Prior systemic therapy (including at least 1 line of chemotherapy and neoadjuvant/adjuvant chemotherapy) must include at least a taxane or anthracycline. Subjects who relapse within 6 months after completion of neoadjuvant/adjuvant chemotherapy are considered as having failed first-line therapy. 5. Capable of swallowing tablets. 6. ECOG performance status of 0-1. 7. Expected survival ≥12 weeks. 8. Adequate function of vital organs, meeting the following criteria (without the use of blood products or growth factors during the screening period): Absolute neutrophil count (ANC) ≥1.5×10⁹/L. Platelet count ≥100×10⁹/L. Hemoglobin ≥9 g/dL. Serum albumin ≥3 g/dL. Thyroid-stimulating hormone (TSH) ≤ULN (if abnormal, T3 and T4 levels should be assessed; subjects with normal T3 and T4 levels are eligible). Total bilirubin ≤1.0×ULN (for subjects with Gilbert's syndrome or liver metastases, total bilirubin ≤1.5×ULN). ALT and AST ≤1.5×ULN (for subjects with liver metastases, ≤3×ULN). Alkaline phosphatase (ALP) ≤2.5×ULN. Renal function within 7 days prior to the first dose: serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min. 9. Women of childbearing potential agree to use highly effective contraception starting at least 7 days prior to the first dose and continuing for 24 weeks after the last dose. A negative serum pregnancy test is required within 7 days prior to the first dose. Exclusion Criteria: 1. Subjects with untreated active brain metastases or leptomeningeal metastases. 2. Participation in any other interventional clinical trial within 28 days prior to the first dose. 3. History of severe allergic reactions to other monoclonal antibodies. 4. Receipt of other antitumor therapies within 28 days prior to the first dose. 5. Uncontrolled hypertension despite antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg). 6. Prior treatment with CTLA-4, Tim-3, or LAG-3 antibodies, or T-cell co-stimulatory therapies (previous use of PD-1 or PD-L1 antibodies is allowed). 7. Prior treatment with anti-angiogenic agents or eribulin chemotherapy. 8. Presence of any active autoimmune disease or a history of autoimmune disease (including but not limited to autoimmune hepatitis, interstitial pneumonitis, uveitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism). Subjects with vitiligo, or childhood asthma that has fully resolved without intervention in adulthood, may be included. Subjects with asthma requiring medical intervention with bronchodilators are excluded. 9. Uncontrolled cardiac clinical symptoms or diseases, including: Heart failure classified as NYHA Class II or higher. Unstable angina. Myocardial infarction within the past year. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention. 10. Urinalysis indicating proteinuria ≥++ or confirmed 24-hour urinary protein ≥1.0 g. 11. Known hereditary or acquired bleeding or thrombotic disorders (e.g., hemophilia, coagulopathy, thrombocytopenia, hypersplenism). 12. Congenital or acquired immunodeficiency (e.g., HIV infection). 13. Receipt of a live vaccine within 4 weeks prior to or during the study period. 14. Allergy or contraindication to the investigational drugs. 15. Underwent surgery within 3 months prior to enrollment or anticipated need for major surgical procedures during the study period.